HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
+11.63%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$1.6B
AUM Growth
+$1.6B
(-8.4%)
Cap. Flow
-$336M
Cap. Flow
% of AUM
-20.97%
Top 10 Holdings %
Top 10 Hldgs %
59.97%
Holding
55
New
14
Increased
10
Reduced
9
Closed
20
Top Buys
| 1 |
Cigna
CI
|
$130M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$79.7M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$77.1M |
| 4 |
Eli Lilly
LLY
|
$66.2M |
| 5 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$61.1M |
Top Sells
| 1 |
AET
Aetna Inc
AET
|
$122M |
| 2 |
Quest Diagnostics
DGX
|
$83.9M |
| 3 |
Hologic
HOLX
|
$81.5M |
| 4 |
Edwards Lifesciences
EW
|
$72.3M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$70.3M |
Sector Composition
| 1 | Healthcare | 90.08% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zimmer Biomet
ZBH
$21B
| $137M | 8.32% | 1,050,000 +50,000 | +5% | +$6.5M |
|
|
2
Cigna
CI
$80.3B
| $130M | 7.94% | +1,000,000 | New | +$130M |
|
3
Biogen
BIIB
$19.4B
| $117M | 7.15% | 375,000 -100,000 | -21% | -$31.3M |
|
|
4
Edwards Lifesciences
EW
$47.8B
| $109M | 6.61% | 900,000 -600,000 | -40% | -$72.3M |
|
5
Labcorp
LH
$23.1B
| $103M | 6.28% | 750,000 -350,000 | -32% | -$48.1M |
|
|
ALXN
6
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $79.7M | 4.85% | +650,000 | New | +$79.7M |
|
|
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $77.1M | 4.7% | +4,250,000 | New | +$77.1M |
|
|
8
Hologic
HOLX
$14.9B
| $73.8M | 4.5% | 1,900,000 -2,100,000 | -53% | -$81.5M |
|
9
Encompass Health
EHC
$12.3B
| $66.9M | 4.08% | 1,650,000 +200,000 | +14% | +$8.11M |
|
|
10
Eli Lilly
LLY
$657B
| $66.2M | 4.03% | +825,000 | New | +$66.2M |
|
|
QGENF
11
DELISTED
QIAGEN NV
QGENF
| $62.4M | 3.8% | 2,275,000 -225,000 | -9% | -$6.17M |
|
|
MNK
12
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $61.1M | 3.72% | +875,000 | New | +$61.1M |
|
13
Incyte
INCY
$16.5B
| $56.6M | 3.45% | +600,000 | New | +$56.6M |
|
14
Merck
MRK
$210B
| $49.9M | 3.04% | 800,000 +511,850 | +178% | +$31.9M |
|
|
BCR
15
DELISTED
CR Bard Inc.
BCR
| $44.9M | 2.73% | +200,000 | New | +$44.9M |
|
|
SYNH
16
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $44.6M | 2.72% | 1,000,000 +600,000 | +150% | +$26.7M |
|
17
Cardinal Health
CAH
$35.5B
| $40.8M | 2.49% | +525,000 | New | +$40.8M |
|
18
Acadia Healthcare
ACHC
$2.12B
| $38.2M | 2.32% | 770,000 +85,780 | +13% | +$4.25M |
|
|
PRAH
19
DELISTED
PRA Health Sciences, Inc.
PRAH
| $38.1M | 2.32% | 675,000 +148,300 | +28% | +$8.38M |
|
20
Collegium Pharmaceutical
COLL
$1.22B
| $27M | 1.64% | 1,400,000 +75,000 | +6% | +$1.44M |
|
21
Pacira BioSciences
PCRX
$1.2B
| $25.5M | 1.55% | 744,280 +494,280 | +198% | +$16.9M |
|
|
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
| $25.2M | 1.54% | 700,000 -1,950,000 | -74% | -$70.3M |
|
|
CVRS
23
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
| $22.2M | 1.35% | 19,981,655 | – | – |
|
24
Perrigo
PRGO
$3.27B
| $18.2M | 1.11% | +197,300 | New | +$18.2M |
|
|
CELG
25
DELISTED
Celgene Corp
CELG
| $15M | 0.92% | +143,850 | New | +$15M |
|